Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBU vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever,Patent ductus arteriosus closure in neonates (off-label)
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Hepatic metabolism primarily via CYP2C9 to inactive metabolites; minor pathways include CYP2C8.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
99% bound primarily to albumin
10-25% bound to albumin at therapeutic concentrations.
0.1-0.2 L/kg, indicating low tissue distribution; predominantly confined to plasma and extracellular fluid.
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral: 80-100% (immediate-release), 70-90% (extended-release); Topical: approximately 5-10% systemic absorption; Intravenous: 100%.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Cr Cl >30 m L/min: no adjustment. Cr Cl 10-30 m L/min: 200 mg every 12 hours; avoid if Cr Cl <10 m L/min.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or avoid. Child-Pugh C: contraindicated due to risk of hepatotoxicity.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; max 40 mg/kg/day. For juvenile idiopathic arthritis: 30-40 mg/kg/day divided every 6-8 hours; max 50 mg/kg/day.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Initiate at lowest effective dose; consider 200 mg every 8-12 hours; monitor renal function and GI bleeding risk.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of peri-operative pain in coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure exacerbation,Renal toxicity,Anaphylactic reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic effects (anemia, bleeding)
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in CABG surgery,Active gastrointestinal bleeding,Advanced renal disease,Third trimester of pregnancy
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Ibuprofen can increase the risk of stomach bleeding when taken with alcohol. No specific food restrictions, but taking with food or milk can reduce GI irritation.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment; contraindicated after 30 weeks gestation.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.03). Considered compatible with breastfeeding by the American Academy of Pediatrics; use lowest effective dose for shortest duration.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Increased plasma volume and renal clearance in pregnancy may reduce drug levels; however, no standard dose adjustment recommended. Use lowest effective dose, avoid in third trimester.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Ibuprofen is a nonselective COX inhibitor with anti-inflammatory, analgesic, and antipyretic effects. Avoid in patients with aspirin allergy, active peptic ulcer, or severe renal impairment. Use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Not recommended in patients with advanced chronic kidney disease (e GFR <30 m L/min/1.73 m²). For acute pain, ibuprofen 200-400 mg every 6 hours PRN. Monitor for signs of GI bleeding, hypertension, and fluid retention.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by your doctor.,Avoid alcohol while taking this medication.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBU vs OFIRMEV, answered by our medical review team.
IBU is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBU and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBU is: 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBU and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBU is classified as Category C. First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of prem. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.